IMVT
Immunovant, Inc.
$24.50
-0.60
(-2.39%)
Mkt Cap
4.99B
Volume
1,938,638
52W Range
12.72-29.25
Sector
Healthcare
Beta
0.67
EPS (TTM)
-2.69
P/E Ratio
-6.26
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (413.84M) | (259.34M) | (210.96M) | (156.73M) | (107.43M) | (66.39M) | (448) | (136.74M) |
| EPS | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.68 |
| Free Cash Flow | (376.63M) | (214.59M) | (188.39M) | (106.37M) | (83.54M) | (53.39M) | (28.60M) | (128.30M) |
| FCF / Share | -2.48 | -1.55 | -1.53 | -0.97 | -0.95 | -1.24 | -1.99 | -12.83 |
| Operating CF | (375.87M) | (214.23M) | (188.19M) | (106.11M) | (83.33M) | (53.36M) | (28.55M) | (128.30M) |
| Total Assets | 776.22M | 666.71M | 405.84M | 515.56M | 412.49M | 109.39M | 405,000 | 113,170 |
| Total Debt | 98,000 | 138,000 | 1.22M | 2.36M | 3.42M | 3.19M | 300,000 | 0 |
| Cash & Equiv | 713.97M | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M | 325,000 | 0 |
| Book Value | 707.45M | 617.76M | 362.49M | 469.82M | 391.48M | 94.07M | 24,552 | (1.50M) |
| Return on Equity | -0.58 | -0.42 | -0.58 | -0.33 | -0.27 | -0.71 | -0.02 | N/A |
| Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (110.64M) | (126.50M) | (120.61M) | (106.45M) | (111.12M) | (109.12M) | (87.15M) | (75.32M) | (51.42M) | (58.66M) | (73.94M) | (59.43M) |
| EPS | -0.61 | -0.73 | -0.71 | -0.64 | -0.76 | -0.74 | -0.60 | -0.52 | -0.36 | -0.45 | -0.57 | -0.46 |
| Free Cash Flow | (92.33M) | (102.52M) | (117.41M) | (110.84M) | (100.57M) | (88.84M) | (76.38M) | (59.85M) | (47.23M) | (60.09M) | (47.41M) | (55.82M) |
| FCF / Share | -0.51 | -0.59 | -0.69 | -0.73 | -0.68 | -0.61 | -0.52 | -0.41 | -0.33 | -0.46 | -0.36 | -0.43 |
| Operating CF | (92.33M) | (102.52M) | (117.41M) | (110.64M) | (100.39M) | (88.65M) | (76.20M) | (59.70M) | (47.10M) | (60.06M) | (47.37M) | (55.79M) |
| Total Assets | 1.05B | 582.96M | 661.44M | 776.22M | 420.93M | 515.71M | 589.68M | 666.71M | 711.45M | 292.07M | 351.22M | 405.84M |
| Total Debt | 0 | 0 | 0 | 98,000 | 23,000 | 47,000 | 69,000 | 138,000 | 306,000 | 614,000 | 919,000 | 1.22M |
| Cash & Equiv | 994.52M | 521.87M | 598.91M | 713.97M | 374.69M | 472.94M | 560.00M | 635.37M | 690.94M | 269.93M | 329.96M | 376.53M |
| Book Value | 986.13M | 519.71M | 608.54M | 707.45M | 352.62M | 449.05M | 544.66M | 617.76M | 679.34M | 251.81M | 299.87M | 362.49M |
| Return on Equity | -0.11 | -0.24 | -0.20 | -0.15 | -0.32 | -0.24 | -0.16 | -0.12 | -0.08 | -0.23 | -0.25 | -0.16 |
IMVT News
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant's treatment for eye disease fails late-stage trial
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus